Express-Scripts included the use of interchangeable insulin biosimilars, which aims to improve cost savings.
Express-Scripts included the use of interchangeable insulin biosimilars, which aims to improve cost savings.
Accessible insulin at a reduced cost is now available through interchangeable biosimilars, enhancing affordability and availability for individuals managing diabetes. In July 2021, the FDA greenlit Semglee as the premier interchangeable biosimilar for Lantus, followed by Rezvoglar in November 2022.
Semglee and Rezvoglar serve as prolonged insulin options utilized to regulate blood sugar levels in both adults and children with type 1 diabetes mellitus, as well as adults with type 2 diabetes mellitus.
This interchangeable classification allows pharmacies to substitute either Semglee or Rezvoglar for Lantus without requiring additional approval from the prescriber, contingent on state pharmacy regulations. Nearly all states permit this practice.
The primary advantage lies in cost savings, as noted by Robert Sardon, a certified pharmacist at Express Scripts Pharmacy who aids diabetes patients. Biosimilars typically enter the U.S. market with initial prices ranging from 15% to 35% lower than the original product.
Furthermore, the availability of interchangeable biosimilar products streamlines processes, saving time for both pharmacists and prescribers. Many pharmacists no longer need pre-approval from prescribers to switch Lantus prescriptions to Semglee or Rezvoglar, contingent on the state of the prescriber and prescription specifics.